Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 22nd May 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.



Polydopamine nanoparticles carrying tumor cell lysate as a potential vaccine for colorectal cancer immunotherapy

Abstract

Polydopamine nanoparticles (PDA NPs) were prepared via dopamine self-polymerization, and then tumor cell lysate (TCL) was covalently attached onto PDA NPs. The TCL loading capacity was 480 μg per mg of PDA NPs, and the resulted TCL@PDA NPs (241.9 nm) had perfect storage stability and negligible cytotoxicity against APCs. The tumor-bearing mice vaccinated with TCL@PDA NPs experienced significant delay in tumor progression due to the sufficient amount of CTLs and M1-type TAM as well as the deficient number of immunosuppression-related cells in tumor tissues. Furthermore, empty PDA NPs had the ability to modulate DCs maturation, delayed the development of tumor by facilitating the production of activated T cells and reducing the subpopulation of MDSCs within the tumor microenvironment. Overall, PDA NPs were expected to be a promising candidate for application as antigen delivery carriers because of the facile antigen loading method as well as the simple and rapid preparation process.

Back to tab navigation

Publication details

The article was received on 03 Jan 2019, accepted on 10 May 2019 and first published on 14 May 2019


Article type: Paper
DOI: 10.1039/C9BM00010K
Biomater. Sci., 2019, Accepted Manuscript

  •   Request permissions

    Polydopamine nanoparticles carrying tumor cell lysate as a potential vaccine for colorectal cancer immunotherapy

    X. wang, N. Wang, Y. Yang, X. Wang, J. Liang, X. Tian, H. Zhang and X. Leng, Biomater. Sci., 2019, Accepted Manuscript , DOI: 10.1039/C9BM00010K

Search articles by author

Spotlight

Advertisements